Nitracrine and its congeners--an overview
- PMID: 7789719
- DOI: 10.1016/0306-3623(94)00143-b
Nitracrine and its congeners--an overview
Abstract
1. An anticancer drug, nitracrine 1-nitro-9(3'3'-dimethylaminopropylamino)acridine (Ledakrin, C-283) exhibits potent cytostatic effects which can be ascribed to interactions of the drug with DNA. 2. The reduction of the nitro group of nitracrine is one of the activation steps leading to the drug covalent binding to DNA and proteins both in subcellular systems and in the cell. 3. DNA-drug non-covalent interactions and covalent complexes are examined in several model systems and compared with the properties of a number of derivatives with programmed structural changes. 4. DNA-protein crosslinks and interstrand crosslinks are detected in the cells following exposition to the drug. 5. The drug exhibits selective toxicity and radiosensitization effects to hypoxic mammalian cells.
Similar articles
-
Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives.Neoplasma. 1999;46(1):50-3. Neoplasma. 1999. PMID: 10355534
-
Anaerobic incubation and mutagenicity of nitracrine analogues in Salmonella typhimurium.Mutagenesis. 1987 Jul;2(4):253-7. doi: 10.1093/mutage/2.4.253. Mutagenesis. 1987. PMID: 3325754
-
Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells.Biochem Pharmacol. 1989 Nov 15;38(22):4095-101. doi: 10.1016/0006-2952(89)90691-6. Biochem Pharmacol. 1989. PMID: 2557039
-
The mode of action of cytotoxic and antitumor 1-nitroacridines. II. In vivo enzyme-mediated covalent binding of a 1-nitroacridine derivative, Ledakrin or Nitracrine, with dna and other macromolecules of mammalian or bacterial cells.Chem Biol Interact. 1983 Feb;43(2):151-73. doi: 10.1016/0009-2797(83)90093-5. Chem Biol Interact. 1983. PMID: 6402314
-
Ledakrin--anticancerous medicine 1-nitro-9(3-dimethylaminopropylamino)-acridine -2HCl-H2O.Mater Med Pol. 1976 Jul-Sep;8(3):237-51. Mater Med Pol. 1976. PMID: 796591 Review. No abstract available.
Cited by
-
The interactions of Pu22 G-quadruplex, derived from c-MYC promoter sequence, with antitumor acridine derivatives-An NMR/MD combined study.Mol Ther Nucleic Acids. 2025 Mar 13;36(2):102513. doi: 10.1016/j.omtn.2025.102513. eCollection 2025 Jun 10. Mol Ther Nucleic Acids. 2025. PMID: 40226330 Free PMC article.
-
Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer.Cancer Biol Ther. 2007 Oct;6(10):1632-7. doi: 10.4161/cbt.6.10.4790. Epub 2007 Jul 24. Cancer Biol Ther. 2007. PMID: 17921700 Free PMC article.
-
The interactions of monomeric acridines and unsymmetrical bisacridines (UAs) with DNA duplexes: an insight provided by NMR and MD studies.Sci Rep. 2023 Mar 1;13(1):3431. doi: 10.1038/s41598-023-30587-y. Sci Rep. 2023. PMID: 36859494 Free PMC article.
-
Acid-Base Equilibrium and Self-Association in Relation to High Antitumor Activity of Selected Unsymmetrical Bisacridines Established by Extensive Chemometric Analysis.Molecules. 2022 Jun 21;27(13):3995. doi: 10.3390/molecules27133995. Molecules. 2022. PMID: 35807234 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
